Telithromycin

Telithromycin

SCHEMBL31576166

CC[C@@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Telithromycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 7/20 1.00
CYP3A5 P20815 6/20 1.00
CYP3A7 P24462 6/20 1.00
CYP3A43 Q9HB55 6/20 1.00
KCNH2 Q12809 4/20 1.00
ABCC4 O15439 1/20 1.00
ABCB11 O95342 1/20 1.00
PTGS1 P23219 1/20 1.00
SLCO1B3 Q9NPD5 1/20 1.00
SLCO1B1 Q9Y6L6 1/20 1.00
GNRHR P30968 2/20 0.54
HDAC1 Q13547 7/20 0.53
HDAC8 Q9BY41 7/20 0.53
HDAC6 Q9UBN7 7/20 0.53
HDAC3 O15379 4/20 0.51
HDAC4 P56524 4/20 0.51
HDAC7 Q8WUI4 4/20 0.51
HDAC2 Q92769 4/20 0.51
HDAC10 Q969S8 4/20 0.51
HDAC11 Q96DB2 4/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Telithromycin SCHEMBL19518975 1.00 CYP3A4 (1.00) CYP3A4CYP3A5CYP3A7CYP3A43KCNH2
Telithromycin SCHEMBL14521662 1.00 CYP3A4 (1.00) CYP3A4CYP3A5CYP3A7CYP3A43KCNH2
Telithromycin SCHEMBL784845 1.00 CYP3A4 (1.00) CYP3A4CYP3A5CYP3A7CYP3A43KCNH2
Telithromycin SCHEMBL18035669 1.00 CYP3A4 (1.00) CYP3A4CYP3A5CYP3A7CYP3A43KCNH2
Telithromycin SCHEMBL12858721 1.00 CYP3A4 (1.00) CYP3A4CYP3A5CYP3A7CYP3A43KCNH2
Telithromycin SCHEMBL14268636 1.00 CYP3A4 (1.00) CYP3A4CYP3A5CYP3A7CYP3A43KCNH2
Telithromycin SCHEMBL10819900 1.00 CYP3A4 (1.00) CYP3A4CYP3A5CYP3A7CYP3A43KCNH2
Telithromycin SCHEMBL15387603 1.00 CYP3A4 (1.00) CYP3A4CYP3A5CYP3A7CYP3A43KCNH2
Telithromycin SCHEMBL5100 1.00 CYP3A4 (1.00) CYP3A4CYP3A5CYP3A7CYP3A43KCNH2
Telithromycin SCHEMBL1878591 1.00 CYP3A4 (1.00) CYP3A4CYP3A5CYP3A7CYP3A43KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250195505-A1 USE OF DEXTROMETHORPHAN IN COMBINATION WITH CYP2D6 AND CYP3A4 ENZYME INHIBITORS FOR THE TREATMENT OF PAIN BIOBINA LLC 2025-06-19 US claimed
US-20250161296-A1 USE OF DEXTROMETHORPHAN IN COMBINATION WITH CYP2D6 AND CYP3A4 ENZYME INHIBITORS FOR THE TREATMENT OF PAIN BIOBINA LLC 2025-05-22 US claimed
US-12303503-B1 Use of dextromethorphan in combination with CYP2D6 and CYP3A4 enzyme inhibitors for the treatment of pain BIOBINA LLC (US) 2025-05-20 US claimed
US-20250195505-A1 USE OF DEXTROMETHORPHAN IN COMBINATION WITH CYP2D6 AND CYP3A4 ENZYME INHIBITORS FOR THE TREATMENT OF PAIN BIOBINA LLC 2025-06-19 US disclosed
US-20250161296-A1 USE OF DEXTROMETHORPHAN IN COMBINATION WITH CYP2D6 AND CYP3A4 ENZYME INHIBITORS FOR THE TREATMENT OF PAIN BIOBINA LLC 2025-05-22 US disclosed
US-12303503-B1 Use of dextromethorphan in combination with CYP2D6 and CYP3A4 enzyme inhibitors for the treatment of pain BIOBINA LLC (US) 2025-05-20 US disclosed